|
|
News Breaks | | | | October 31, 2012 | | 09:28 EDT |  | CLDX | Celldex data encouraging, says Roth Capital
Roth Capital believes that Phase I results for Celldex's CDX-1401 cancer vaccine showed strong immunological data and encouraging clinical activity for late stage patients with multiple tumor types.The firm maintains a $9 target and Buy rating on the shares. | |
|
News For CLDX From The Last 14 Days Check below for free stories on CLDX the last two weeks. |
|
|
| May 10, 2013 | | 07:24 EDT |  | CLDX | Credit Suisse to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
